Ampersand Capital Partners announced the closing of Ampersand 2026 Limited Partnership (AMP-26) with $1.5 billion in limited partner commitments, reaching its hard cap in a single close less than five months after launch. The fund represents Ampersand’s twelfth primary fund since 1992 and attracted commitments from a broad range of institutional investors, including endowments, foundations, pension plans, insurance companies, funds of funds, and family offices.
Founded in 1988, Ampersand is a middle-market private equity firm focused on healthcare investments. The firm manages more than $4 billion in assets and has offices in Boston, Amsterdam, and London. AMP-26 will continue Ampersand’s longstanding strategy of partnering with founders and management teams through both majority and minority investments in healthcare and life sciences companies generating between $10 million and $200 million in revenue with positive EBITDA.
For more than 35 years, Ampersand has focused on helping healthcare businesses accelerate growth and scale into market leaders. The firm said the new fund will support investments in companies that provide mission-critical products, tools, and services to the healthcare and life sciences innovation ecosystem.
Support: McDermott Will & Schulte LLP served as legal counsel to Ampersand in connection with the fundraising process.
KEY QUOTE:
“We are grateful for the exceptional support from both existing and new investors, and for their continued confidence in Ampersand’s specialized investment strategy. At its core, this strategy is focused on partnering with founders and management teams to build market-leading companies that provide mission-critical tools and services to the innovation ecosystem within healthcare and life sciences.”
Herb Hooper, Managing Partner, Ampersand Capital Partners
